Johnson & Johnson vs Eli Lilly

Johnson & Johnson (JNJ), health care, and Eli Lilly (LLY), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.

Eli Lilly is worth $1.26T on the stock market and Johnson & Johnson $675.5B: Eli Lilly is valued at 86% more. Johnson & Johnson trades at 42.6 times earnings and Eli Lilly at 45.9. Over the past year Johnson & Johnson's share price has moved +41.3% and Eli Lilly's +39.0%.

Key facts

Johnson & Johnson market value
$675.5B
Eli Lilly market value
$1.26T
Johnson & Johnson P/E
42.6
Eli Lilly P/E
45.9
Johnson & Johnson revenue
$94.2BFY to 2025-12-28
Eli Lilly revenue
$65.2BFY to 2025-12-31
Superinvestors holding both
12

Market values as of .

Johnson & Johnson vs Eli Lilly: every measure side by side
Measure Johnson & Johnson Eli Lilly
SectorHealth CareHealth Care
Country United States United States
Fiscal year ends2025-12-282025-12-31
Size
Market cap$675.5Blower$1.26Thigher
Revenue$94.2Bhigher$65.2Blower
Earnings$26.8Bhigher$20.6Blower
Employees138,200higher50,000lower
Total assets$199.2Bhigher$112.5Blower
Valuation
P/E42.6lower45.9higher
P/S7.2lower19.3higher
P/B8.3lower31.3higher
Dividend yield1.87%higher0.47%lower
Profitability
Operating margin——
Balance sheet
Net assets$81.5Bhigher$26.5Blower
Total liabilities$117.7Bhigher$85.9Blower
Total debt$47.9Bhigher$42.5Blower
Cash on hand$19.7Bhigher$7.3Blower
Price change
Today-0.68%higher-1.22%lower
1 year+41.3%higher+39.0%lower

Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.

Loading the one-year price chart…

Which superinvestors hold them

From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.

Percentages are each holding's share of that investor's reported portfolio (under "Both": Johnson & Johnson / Eli Lilly). Who owns JNJ · Who owns LLY

Further comparisons

Learn

Questions and answers

Which is bigger, Johnson & Johnson or Eli Lilly?

By market value, Eli Lilly is the larger: $1.26T against $675.5B for Johnson & Johnson. By revenue in its latest fiscal year, Johnson & Johnson is the larger: $94.2B against $65.2B for Eli Lilly.

Which has the higher P/E ratio?

Eli Lilly: 45.9, against 42.6 for Johnson & Johnson. A higher P/E means the market pays more for each dollar of the last twelve months' earnings; on its own it does not say which is the better value.

Which has the higher dividend yield?

Johnson & Johnson: 1.87%, against 0.47% for Eli Lilly. Dividend yield is the last twelve months' dividends as a share of today's share price.

Which has more debt?

Johnson & Johnson: $47.9B, against $42.5B for Eli Lilly. Total debt is borrowings at the end of the latest fiscal year, as each company reported it; it is not set against cash here.

Which superinvestors own both Johnson & Johnson and Eli Lilly?

In their latest 13F filings, Jeremy Grantham (co-founder), Ken Fisher, Mairs & Power team, Ray Dalio (founder), Cliff Asness, Ken Griffin, Mario Gabelli, George Soros, Jensen team, Murray Stahl, Rajiv Jain and Dodge & Cox team hold both.

Cite this page

Funkfolio, “Johnson & Johnson vs Eli Lilly”, data as of 17 November 2026. https://funkfolio.com/compare/jnj-vs-lly

Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.